
================================================================================
 CASE STUDY ANALYSIS - COMPREHENSIVE TEST (ALL 5 TABS)
================================================================================
  Drug: BARICITINIB
  Started: 2025-12-04 20:17:58.943937
  Output will be saved to: test_outputs\workflow_test_20251204_201758.txt

Initializing agent...
Agent ready.


================================================================================
 TAB 1: DRUG INFO FOR 'BARICITINIB'
================================================================================

  Drug Name:    baricitinib
  Generic Name: baricitinib
  Mechanism:    Janus Kinase Inhibitor
  Manufacturer: Eli Lilly and Company

  Approved Indications (4):
    1. adults with severe alopecia areata
    2. covid-19 in certain hospitalized adults
    3. adults with moderately-to-severely active rheumatoid arthritis
    4. moderately-to-severely active rheumatoid arthritis

--- Validation ---
  PASS: generic_name populated
  PASS: mechanism concise: 'Janus Kinase Inhibitor'
  PASS: Found 4 indications

================================================================================
 TAB 2: CASE SERIES SEARCH FOR 'BARICITINIB'
================================================================================

  Drug: baricitinib
  Exclude: ['adults with severe alopecia areata', 'covid-19 in certain hospitalized adults', 'adults with moderately-to-severely active rheumatoid arthritis']...

Searching... (may take 1-2 mins)

--- Results: 44 papers ---
  Full text (PMC): 21
  LLM verified: 44

  Diseases (36):
    - vitiligo: 3
    - atopic dermatitis: 3
    - juvenile idiopathic arthritis: 2
    - adult-onset Still's disease: 2
    - autoinflammatory interferonopathies: 2
    - systemic lupus erythematosus: 2
    - multiple dermatologic conditions: 1
    - dermatomyositis: 1
    - giant cell arteritis: 1
    - type I interferonopathies: 1
    - uveitis: 1
    - folliculitis decalvans: 1
    - synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: 1
    - polymyalgia rheumatica and giant cell arteritis: 1
    - dystrophic epidermolysis bullosa: 1

--- Sample Papers ---

  1. Oral tofacitinib, baricitinib and upadacitinib monotherapy for steroid...
     PMID: 38853646 | Disease: vitiligo
     Full text: False
     Why: Prospective case series with patient outcomes for steroid-resistant vitiligo...

  2. Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Dis...
     PMID: 38051858 | Disease: multiple dermatologic conditions
     Full text: False
     Why: Case series with 6 patients showing efficacy outcomes in dermatomyositis, hidrad...

  3. JAK inhibitors in refractory dermatomyositis: A case series....
     PMID: 38887110 | Disease: dermatomyositis
     Full text: False
     Why: Retrospective cohort study of 14 patients with efficacy data showing significant...

  4. Clinical experience and safety of Janus kinase inhibitors in giant cel...
     PMID: 37304255 | Disease: giant cell arteritis
     Full text: True
     Why: Retrospective case series of 15 patients with efficacy data showing CRP reductio...

  5. Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies:...
     PMID: 35418997 | Disease: type I interferonopathies
     Full text: True
     Why: Case series assessing efficacy and safety in type I interferonopathies including...

--- Validation ---
  PASS: Found 44 papers
  WARN: 1 potentially irrelevant papers
    - Pharmacokinetics, Pharmacodynamics, and Proposed D...

================================================================================
 TAB 3: DATA EXTRACTION (WITH PMC FULL TEXT)
================================================================================

  Extracting from 21 papers with PMC full text...
  (This may take several minutes)

  1. [PMC] Clinical experience and safety of Janus kinase inhibito...
     PASS: Disease=Giant cell arteritis, N=15, Response=73.0%
     Efficacy: JAK inhibitors showed significant efficacy with rapid CRP reduction within 3 mon...
     Safety: Two patients experienced serious infections but JAK inhibitor therapy was retain...

  2. [PMC] Janus Kinase Inhibitors in the Treatment of Type I Inte...
     WARN: No data extracted

  3. [PMC] Case report: Effectiveness of Janus kinase inhibitors i...
     PASS: Disease=isolated noninfectious uveitis, N=3, Response=100.0%
     Efficacy: All three patients with refractory isolated noninfectious uveitis achieved compl...
     Safety: No significant side effects were observed in any patients throughout the follow-...

  4. [PMC] A Case Report of JAK Inhibitors Therapy for Adult-Onset...
     PASS: Disease=Adult-Onset Still's Disease, N=1, Response=100.0%
     Efficacy: JAK inhibitor therapy provided rapid and sustained clinical improvement with com...
     Safety: Treatment was well-tolerated with only minor renal function abnormalities noted ...

  5. [PMC] Use of Baricitinib in a patient with treatment-resistan...
     PASS: Disease=pyoderma gangrenosum, N=1, Response=100.0%
     Efficacy: During 12 weeks of baricitinib therapy, the patient showed significant improveme...
     Safety: No adverse events directly attributed to baricitinib were reported in this case....

  6. [PMC] Mixed results with baricitinib in biological-resistant ...
     PASS: Disease=Adult-onset Still's disease (AOSD) and undifferentiated systemic autoinflammatory disease, N=3, Response=67.0%
     Efficacy: Mixed results with baricitinib in biological-resistant AOSD patients. Two of thr...
     Safety: One patient developed Pneumocystis jirovecii pneumonia at 7 months of treatment,...

  7. [PMC] Assessment of Clinical Response to Janus Kinase Inhibit...
     PASS: Disease=Familial chilblain lupus with TREX1 mutation, N=3, Response=100.0%
     Efficacy: All 3 patients showed significant improvement of cutaneous lupus lesions with su...
     Safety: No severe adverse reactions were reported during the 3-month treatment period. T...

  8. [PMC] Rheumatological complaints in H syndrome: from inflamma...
     PASS: Disease=H syndrome, N=1, Response=None%
     Efficacy: Baricitinib monotherapy provided only partial improvement in arthritis symptoms ...
     Safety: No adverse events were reported during the 12-month treatment period with barici...

  9. [PMC] Off-label use of Baricitinib improves moderate and seve...
     PASS: Disease=atopic dermatitis, N=23, Response=None%
     Efficacy: Baricitinib 2mg daily for 4 weeks improved clinical symptoms in moderate and sev...
     Safety: No significant adverse events or toxicities were reported during the 4-week trea...

  10. [PMC] Baricitinib restrains the immune dysregulation in patie...
     WARN: No data extracted

  11. [PMC] Alopecia Areata Following the Use of Belimumab in a Pat...
     PASS: Disease=Systemic lupus erythematosus, N=1, Response=100.0%
     Efficacy: Patient showed significant improvement in alopecia universalis with nearly compl...
     Safety: No adverse events reported during baricitinib treatment. Patient was able to tap...

  12. [PMC] JAK1/2 inhibition with baricitinib in the treatment of ...
     PASS: Disease=Autoinflammatory interferonopathies (CANDLE, SAVI, and other interferonopathies), N=18, Response=67.0%
     Efficacy: Significant improvements in daily symptom scores, corticosteroid dose reduction,...
     Safety: Most common adverse events were upper respiratory infections and gastroenteritis...

  13. [PMC] Disease flares with baricitinib dose reductions and dev...
     PASS: Disease=CANDLE/PRAAS (Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature/Proteasome-Associated Autoinflammatory Syndrome), N=10, Response=50.0%
     Efficacy: 50% of patients achieved lasting clinical remission on baricitinib with normaliz...
     Safety: Higher exposures required for CANDLE/PRAAS led to significant safety concerns in...

  14. [PMC] Sustained Interferon Signature Suppression With Anifrol...
     PASS: Disease=STING-Associated Vasculopathy with Onset in Infancy (SAVI), N=1, Response=None%
     Efficacy: Baricitinib monotherapy failed to control disease despite over 10 years of treat...
     Safety: Baricitinib caused significant viral reactivations including BK viruria/viremia,...

  15. [PMC] Pharmacokinetics, Pharmacodynamics, and Proposed Dosing...
     PASS: Disease=CANDLE and SAVI (Mendelian interferonopathies), N=18, Response=None%
     Efficacy: Baricitinib demonstrated dose-dependent decreases in interferon biomarkers, conf...
     Safety: No specific safety outcomes were reported in the abstract or available text. The...

  16. [PMC] Combination of Baricitinib and Phototherapy in Adults W...
     PASS: Disease=vitiligo, N=49, Response=None%
     Efficacy: Baricitinib combined with narrowband UV-B phototherapy showed significant improv...
     Safety: Safety outcomes were not detailed in the provided abstract, though the study ass...

  17. [PMC] Rapid response of lichen planus to baricitinib associat...
     PASS: Disease=cutaneous lichen planus, N=12, Response=83.3%
     Efficacy: 83.3% of patients achieved treatment response with 50% or greater PGA score redu...
     Safety: Total of 12 adverse events with only one mild AE (neutropenia) deemed probably r...

  18. [PMC] Efficacy and safety of baricitinib in Japanese patients...
     PASS: Disease=Autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, and AGS), N=9, Response=None%
     Efficacy: Baricitinib showed efficacy in NNS/CANDLE and SAVI patients with decreased daily...
     Safety: All patients experienced at least one adverse event. Common events included BK v...

  19. [PMC] Oral Baricitinib in the Treatment of Cutaneous Lichen P...
     PASS: Disease=Cutaneous lichen planus, N=12, Response=83.3%
     Efficacy: 83.3% of patients with cutaneous lichen planus showed clinical response to baric...
     Safety: No specific adverse events were reported in the abstract or available text....

  20. [PMC] Baricitinib for refractory Takayasu arteritis: a prospe...
     PASS: Disease=Takayasu arteritis (refractory), N=10, Response=60.0%
     Efficacy: At 6 months, 60% of patients achieved overall treatment response. During follow-...
     Safety: Treatment was well tolerated with no severe adverse events reported. Only one pa...

  21. [PMC] A retrospective study of the efficacy of JAK inhibitors...
     PASS: Disease=rheumatoid arthritis-interstitial lung disease, N=31, Response=83.9%
     Efficacy: JAK inhibitors showed stability or improvement of RA-ILD in 83.9% of patients ov...
     Safety: No specific adverse events reported in the study. Safety profile appears accepta...

--- Validation ---
  Successful: 19/21

================================================================================
 TAB 4: SCORING & PRIORITIZATION
================================================================================

  Scoring 19 extractions...

  Fetching market intelligence for each disease...
  (This requires web search for epidemiology & standard of care)
  Market data fetched for 10/19 diseases

--- Scored Opportunities ---

  1. Giant cell arteritis
     Clinical:  7.5/10 (50% weight)
     Evidence:  8.7/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     8.0/10

  2. isolated noninfectious uveitis
     Clinical:  9.5/10 (50% weight)
     Evidence:  6.3/10 (25% weight)
     Market:    9.7/10 (25% weight)
     TOTAL:     8.8/10

  3. Adult-Onset Still's Disease
     Clinical:  9.5/10 (50% weight)
     Evidence:  7.0/10 (25% weight)
     Market:    9.3/10 (25% weight)
     TOTAL:     8.8/10

  4. pyoderma gangrenosum
     Clinical:  9.5/10 (50% weight)
     Evidence:  4.7/10 (25% weight)
     Market:    8.7/10 (25% weight)
     TOTAL:     8.1/10

  5. Adult-onset Still's disease (AOSD) and undifferentiated systemic autoinflammatory disease
     Clinical:  5.5/10 (50% weight)
     Evidence:  7.3/10 (25% weight)
     Market:    8.7/10 (25% weight)
     TOTAL:     6.8/10

  6. Familial chilblain lupus with TREX1 mutation
     Clinical:  9.5/10 (50% weight)
     Evidence:  5.7/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     8.2/10

  7. H syndrome
     Clinical:  9.0/10 (50% weight)
     Evidence:  7.0/10 (25% weight)
     Market:    8.0/10 (25% weight)
     TOTAL:     8.2/10

  8. atopic dermatitis
     Clinical:  9.0/10 (50% weight)
     Evidence:  7.0/10 (25% weight)
     Market:    10.0/10 (25% weight)
     TOTAL:     8.8/10

  9. Systemic lupus erythematosus
     Clinical:  9.5/10 (50% weight)
     Evidence:  7.0/10 (25% weight)
     Market:    9.7/10 (25% weight)
     TOTAL:     8.9/10

  10. Autoinflammatory interferonopathies (CANDLE, SAVI, and other interferonopathies)
     Clinical:  7.5/10 (50% weight)
     Evidence:  8.7/10 (25% weight)
     Market:    7.3/10 (25% weight)
     TOTAL:     7.7/10

  11. CANDLE/PRAAS (Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature/Proteasome-Associated Autoinflammatory Syndrome)
     Clinical:  4.5/10 (50% weight)
     Evidence:  8.7/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     6.5/10

  12. STING-Associated Vasculopathy with Onset in Infancy (SAVI)
     Clinical:  3.0/10 (50% weight)
     Evidence:  7.0/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     5.3/10

  13. CANDLE and SAVI (Mendelian interferonopathies)
     Clinical:  5.5/10 (50% weight)
     Evidence:  7.0/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     6.6/10

  14. vitiligo
     Clinical:  7.0/10 (50% weight)
     Evidence:  7.0/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     7.3/10

  15. cutaneous lichen planus
     Clinical:  9.5/10 (50% weight)
     Evidence:  6.3/10 (25% weight)
     Market:    8.7/10 (25% weight)
     TOTAL:     8.5/10

  16. Autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, and AGS)
     Clinical:  6.5/10 (50% weight)
     Evidence:  5.7/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     6.8/10

  17. Cutaneous lichen planus
     Clinical:  7.5/10 (50% weight)
     Evidence:  6.3/10 (25% weight)
     Market:    8.7/10 (25% weight)
     TOTAL:     7.5/10

  18. Takayasu arteritis (refractory)
     Clinical:  8.5/10 (50% weight)
     Evidence:  7.0/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     8.1/10

  19. rheumatoid arthritis-interstitial lung disease
     Clinical:  8.5/10 (50% weight)
     Evidence:  9.3/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     8.7/10

--- Validation ---
  Scored: 19/19

================================================================================
 TAB 5: FULL ANALYSIS SUMMARY
================================================================================

  Drug: baricitinib
  Mechanism: Janus Kinase Inhibitor
  Approved Indications: 4
  Papers Found: 44
  Papers with PMC Full Text: 21
  Extractions: 19

--- Top Off-Label Indications ---
    vitiligo: 3 papers
    atopic dermatitis: 3 papers
    juvenile idiopathic arthritis: 2 papers
    adult-onset Still's disease: 2 papers
    autoinflammatory interferonopathies: 2 papers
    systemic lupus erythematosus: 2 papers
    multiple dermatologic conditions: 1 papers
    dermatomyositis: 1 papers
    giant cell arteritis: 1 papers
    type I interferonopathies: 1 papers

--- Validation ---
  PASS: Full pipeline executed

================================================================================
 FINAL SUMMARY
================================================================================
  Tab 1 Drug Info:   PASS
  Tab 2 Search:      PASS (44 papers)
  Tab 3 Extraction:  PASS (19 successful)
  Tab 4 Scoring:     PASS (19 scored)
  Tab 5 Analysis:    PASS

  Total API Tokens: 175,424
  Completed: 2025-12-04 20:27:36.502978

  JSON data saved to: test_outputs\workflow_data_20251204_201758.json

================================================================================
 GENERATING FINAL REPORT
================================================================================
  Excel report: data\case_series\baricitinib_report_20251204_201758.xlsx
  Full JSON: data\case_series\baricitinib_full_20251204_201758.json
